血清膜联蛋白A2与口腔鳞癌病人放化疗敏感性及预后的关系

Relationships between serum annexin A2 and chemosensitivity and prognosis of patients with oral squamous cell carcinoma

目的分析血清膜联蛋白A2(ANXA2)在中晚期口腔鳞癌(OSCC)病人中的表达,并探讨其与放化疗敏感性及预后的关系。方法将2013年2月至2015年2月广州中医药大学第一附属医院收治的68例中晚期OSCC病人纳入为研究组,另将68例同期体检健康者为对照组,OSCC病人行放化疗治疗,收集受试者血清,采用酶联免疫吸附法(ELISA)检测血清ANXA2水平,比较两组血清ANXA2水平,与病理参数、放化疗敏感性及预后的关系。结果研究组病人血清ANXA2水平(28.15±6.24)µg/L明显高于对照组(13.92±4.18)µg/L(P<0.05);血清ANXA2表达与OSCC病人年龄、性别、肿瘤大小无关(P>0.05),与TNM分期、分化程度、淋巴结转移、远处转移相关(P<0.05);ANXA2高表达组病人放化疗总有效率为54.84%,明显低于ANXA2低表达组病人总有效率的78.38%(P<0.05);OSCC病人血清ANXA2低表达病人5年中位数生存时间为(37.00±5.28)个月,高表达组5年中位数生存时间为(28.00±3.89)个月,两组病人预后5年中位数生存时间比较差异有统计学意义(P<0.05)。结论OSCC病人血清ANXA2高表达,并与TNM分期、分化程度、淋巴结转移、远处转移相关,ANXA2高表达者的放化疗敏感性低,预后差。

Objective To analyze the expression of serum annexin A2(ANXA2)in patients with advanced oral squamous cell carcinoma(OSCC),and to explore its relationship with chemosensitivity and prognosis.Methods Sixty-eight patients with advanced OSCC admitted to The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine from February 2013 to February 2015 were included as the study group,and 68 healthy people in the same period were selected as the control group.OSCC patients were treated with radiotherapy and chemotherapy,serum of whom was collected,and enzyme-linked immunosorbent assay(ELISA)was used to detect serum ANXA2 level.The relationships between serum ANXA2 level with pathological parameters,chemoradiotherapy sensitivity,and prognosis were compared between the two groups.Results The serum ANXA2 level of the study group was significantly higher than that of the control group[(28.15±6.24)µg/L vs.(13.92±4.18)µg/L;P<0.05].The serum expression of ANXA2 was not correlated with age,gender,and tumor size of OSCC patients(P>0.05),but correlated with TNM staging,differentiation degree,lymph node metastasis,and distant metastasis(P<0.05).The total effective rate of chemoradiation in patients with high ANXA2 expression was 54.84%,which was significantly lower than 78.38%in patients with low ANXA2 expression(P<0.05).The 5-year median survival time of OSCC patients with low ANXA2 expression was(37.00±5.28)months,and that of patients with high ANXA2 expression was(28.00±3.89)months;there was significant difference between the two groups(P<0.05).Conclusion The serum ANXA2 is highly expressed in OSCC patients,and is associated with TNM staging,differentiation,lymph node metastasis,and distant metastasis.Patients with high expression of ANXA2 have low sensitivity to chemoradiotherapy and poor prognosis.